The Antidote: Inside the World of New Pharma (81 page)

layoffs and,
95
–96

management style and skills of,
144
–46,
161
,
201
,
206
–7

Milestone Day and,
321
–23

Murcko’s relationship with,
333
–34

NDA and,
227
–29,
232

nucs and,
299
–300,
347

phenotypic screening and,
205
–6

pressures on,
207
,
222

reorganization of,
333
–37

succession and,
196
,
338
–39

transformational life bell of,
289
–90,
361

multiple sclerosis (MS),
93
,
336
–37,
380

Murcko, Mark,
30
,
56
,
65
,
71
,
113
,
116
,
143
,
145
–46,
157
–58,
160
,
218
,
257

Boger’s relationship with,
28
,
145

Boger’s retirement and,
196
–97,
206

CF and,
80
,
335

departure of,
334
–38,
379

disruptive technology and,
145
,
205
–6

HCV and,
32
–35,
37
,
63

HIV and,
13
–14,
17
–18,
28
–29,
91
,
335

Incivek and,
222
,
232
,
289
,
335

kinases and,
54
–55,
335

Kwong’s recruitment and,
40
–41

lawsuit against,
75
–76

management style and skills of,
29
,
79
,
205
–7

Milestone Day and,
323
–24

Mueller’s relationship with,
333
–34

phenotypic screening and,
205
–6

speeches of,
13
–15,
75

systems biology and,
206
–7

Vertex-Novartis partnership and,
57
–58

and Vertex’s acquisition of Aurora,
78
–79

Namchuk, Mark,
144
,
334
,
336
–37

National Institutes of Health (NIH),
23
,
26
,
32
,
68
,
119
,
144
,
156
,
202
,
300

Nature
,
29
,
54
–55

Nature Reviews
,
177

Nazis,
366

NBC Nightly News
,
263

Negulescu, Paul,
117
–18,
144

CF and,
79
–81,
118
,
127
,
180
,
343

Olson’s interview with,
80
–81

pain program and,
126
–27

and Vertex’s acquisition of Aurora,
78
–79

nerves, nervous system,
49
,
72
–73,
75
,
92
,
126
,
215
–16,
334
,
336
–37

Neuberger, Tim,
125
–26

new drug applications (NDAs),
157
,
183
,
327

Incivek and,
194
,
207
,
214
–15,
222
–24,
226
–29,
231
–33,
336

Kalydeco and,
237
,
345

Merck and,
226
–29,
231
,
233
,
238
,
244

New England Journal of Medicine
,
346

New Pharma,
175
,
214
,
380

New Yorker
,
12

New York Times
,
20
,
36
,
66
,
122
,
185
,
195
,
300
,
342

HCV and,
76
,
139
,
166

9/11,
73
,
128
,
146
,
163
,
246
,
277
,
382

Novartis,
123
,
163
,
357

Gleevec and,
57
,
131

Vertex’s partnership with,
56
–59,
65
,
72
,
78
,
85
,
87
–88,
106
–7,
114
,
144
,
177
,
206
,
336

Nucinator, The
,
349

nucleoside analogs (nucs),
197
,
287
–88,
314
–15,
346

of Alios,
299
–300,
314
,
347
,
358
,
362
,
372
,
375
,
378

HCV and,
151
,
182
–83,
220
,
261
–62,
299
,
325
,
347
,
349
,
352
–53,
355
,
358
,
360
,
362
–63,
372
–73,
378
–79

HIV and,
24
,
46
,
148
,
357

Obama, Barack,
176
,
187
,
202
,
255
,
300
,
312
,
346

health care legislation of,
5
,
195
,
214
,
217
,
219
–20,
237
,
366
,
372
,
377

on stem cell research,
204
–5

Occupy Wall Street,
328
,
330
,
346

off-label drugs, off-label marketing,
46
,
65
,
166
,
195
,
267
,
372

Olson, Eric,
80
–82,
118
,
140
–43,
179
–82,
251
,
295
,
297
,
335
,
344
,
362
,
381
,
386

omeprazole (Prilosec),
123
,
163
,
210

Ordonez, Claudia,
180

Pace, Megan,
295
,
339
,
386

Incivek and,
243
–44,
264
,
272
,
275
,
285
,
287
–88

pain program,
126
–27

Pan Am Flight 103 bombing,
5

pancreas,
67
,
69
,
179
,
249
,
346

Partridge, Michael,
243
,
383

CF and,
295
,
313
,
343
,
345
,
364
–65

earnings calls and,
175
–76,
307
,
309
,
339
–40

HCV and,
262
,
350
,
356
,
359

Incivek and,
264
,
285
,
287
,
307
,
313
,
328
–30,
332

Kalydeco and,
367
–68,
370

stock market declines and,
312
–13

patents,
25
,
46
–48,
74
,
84
,
192
,
202
,
245
,
298
,
316
–17

generic drugs and,
184
,
195

HCV and,
47
–48,
101

HIV and,
30
–32,
35
–36,
357

Patrick, Deval,
153
,
156
,
172
–74,
383

Paulson, Henry,
178
–79,
187

Peattie, Debra,
21
–23,
37
,
105
,
232

Pegasys,
61
,
165
–66,
213
,
284
,
348

Pegintron,
61
,
165
–66,
213
,
221
,
284

penicillin,
15
,
152

peptides,
16
,
34
,
37
,
64

Pfizer,
6
,
46
,
65
,
80
,
98
,
114
,
240
,
277
,
284

finances of,
4
,
88
,
195
,
245
–46,
251

JAK inhibitors and,
177
,
215
,
317
–18

Wyeth acquired by,
195
,
199
–200

pharmaceutical companies, pharmaceutical industry,
145
,
162
,
260
,
311
,
346
,
385

China and,
169
–70,
172
–73,
326

Clinton and,
11
,
46

competition in,
1
–4

corruption in,
166
,
279
–80

finances in,
5
–6,
11
–12,
15
,
171

grand contradiction in,
246
–47

in history,
3
–5,
7

mergers and acquisitions in,
115
,
199
–200

profitability of,
2
–6

public image and relations of,
115
,
280

regulation of,
6
,
15
,
35

Pharmaceutical Research and Manufacturers of America (PhRMA),
204
,
217

pharmacokinetics (PK),
79
,
160

CF and,
121
,
125
,
295
,
302

HCV and,
63
,
95
,
111

HIV and,
25
,
35

pharmaplasia,
385
,
387

Pharmasset,
287
–88,
314

comparisons between Vertex and,
261
–62

finances of,
262
,
329
,
333
,
346
,
354
,
359

Gilead’s acquisition of,
357
,
363

HCV and,
182
–83,
220
,
261
–62,
324
–25,
327
,
329
,
342
,
347
–51,
353
–56,
359
,
363

as takeover target,
197
,
354
–55

phenotypic screening,
205
–6,
335

Pollack, Andrew,
342

polymerase, polymerase inhibitors,
151
,
225

HCV and,
39
,
49
,
182
–83,
199
,
215
,
349

polymers,
112
,
124
,
132
,
239

polyproteins,
22
,
33

Porges, Geoffrey,
197
,
317

CF and,
250
–51,
298
,
343
,
345
,
353
–54,
361
,
368

HCV and,
102
,
250
–56,
363

Incivek and,
131
,
307
,
315
,
332
–33,
352
–53,
355

and Pharmasset as takeover target,
354
–55

Vertex research reports of,
96
–97,
101
–2

on Vertex’s collaborations,
102
,
107

positive deviance,
157
–58,
265
,
379
,
386

potentiators,
81
,
120
–21,
125
,
140
–41,
179
,
249
–50,
298

pralnacasan (VX-740),
47
,
49
,
52
,
77
–78,
85
,
87
,
92
–93,
99
–100,
106
,
129
,
131
,
146
,
177
,
215
,
335
,
368

predictive modeling,
75

Price, Schaefer,
349
,
354
–55,
358
–59

prices,
43
,
75
,
166
,
187
,
202
,
204
,
217
,
261
,
287
,
311
,
329
,
331
,
333
,
370
,
376
,
388

CF and,
111
,
250
,
297
–98,
343
,
371

Clinton on,
11
,
15
,
26
,
45
–46,
115

Incivek and,
194
,
247
,
277
,
285
–86,
288
,
315
–16,
324
,
332

Kalydeco and,
305
,
361
,
377
–78

and value of Vertex,
350
,
352

Victrelis and,
283
–84,
286
,
342

Prilosec (omeprazole),
123
,
163
,
210